In an exclusive conversation with Business Retail World, Dr Rohan Goyal, co-founder Nuvana outlines how trust, clinical rigour and patient-first ethics are shaping Nuvana’s growth in India’s evolving healthcare retail landscape
As healthcare increasingly intersects with retail-led wellness models, clinics like Nuvana are positioning themselves at the forefront of a more consumer-centric, outcome-driven ecosystem. In this exclusive conversation, Dr Rohan Goyal, Founder and Regenerative Medicine Specialist at Nuvana, shares how the brand is building credibility, scaling responsibly, and navigating the commercial realities of modern healthcare while keeping patient trust at its core.
Regenerative medicine is gaining traction globally. What inspired you to establish Nuvana, and how do you see the field evolving in India over the next decade?
What inspired me to establish Nuvana was a clear and recurring gap in healthcare—patients were often being treated for symptoms, but not enough attention was given to recovery, repair, prevention, and long-term quality of life.
I felt there was a need for a platform that combines medical science, advanced therapies, and a personalised approach to healing. Regenerative medicine represents a shift in mindset—it’s not just about managing disease, but about supporting the body’s ability to repair and function better.
In India, the next decade will be transformative. Regenerative medicine will move from being perceived as niche to becoming a more structured part of mainstream care—especially in orthopaedics, pain management, sports recovery, metabolic health, longevity, and preventive care.
India has the clinical talent, entrepreneurial energy, and patient volume to become a key market. However, growth must be responsible, backed by strong protocols, ethical adoption, better evidence generation, and clear regulation. Those who build with discipline and credibility will shape the future.
As both a clinician and entrepreneur, how do you balance medical ethics, patient outcomes, and the commercial realities of building a healthcare venture?
For me, the balance starts with one principle: the patient must always come before the business model. In healthcare, if you compromise ethics for growth, you may generate revenue, but you won’t build trust—and without trust, nothing sustainable can exist.
The traditional concept of a family doctor was built on this trust—no overprescription, consistent outcomes, and long-term relationships. That is something we try to emulate at Nuvana.
We evaluate every decision through three filters: Is it clinically appropriate for the patient?, Is it safe and transparently communicated? and can it be delivered in a sustainable and scalable way? If something doesn’t meet the first two criteria, it doesn’t move forward—regardless of its commercial appeal.
Commercial success, in my view, should be the outcome of consistently doing the right things, not the objective at the cost of integrity. Ethical care, strong outcomes, and patient trust ultimately become the biggest business advantages.
Regenerative therapies often face scepticism and regulatory scrutiny. How does Nuvana ensure scientific credibility, safety, and trust?
Scepticism is both natural and necessary—any evolving field in medicine should be rigorously questioned. At Nuvana, we welcome scrutiny rather than resist it.
Scientific credibility begins with honesty—clearly distinguishing what is established, what is emerging, and what is still investigational. We don’t position regenerative medicine as a miracle solution, but as a promising and evolving field that requires discipline.
Safety is non-negotiable. This includes robust protocols, careful patient selection, informed consent, strict hygiene standards, proper documentation, and clear escalation pathways when conventional treatments are more appropriate.
Trust is built when patients feel informed, not sold to. Similarly, credibility within the medical community comes from focusing on evidence, outcomes, and ethics. For this field to mature in India, institutions must be transparent, collaborative, and accountable. Accountability, in particular, is a culture we are actively building.
India is emerging as a hub for advanced healthcare solutions. What role can regenerative medicine play in strengthening the country’s innovation ecosystem and medical tourism industry?
Regenerative medicine can act as a bridge between India’s clinical excellence and its innovation ambitions. The country already has strong medical talent, growing infrastructure, and a significant cost advantage compared to global markets.
If developed responsibly, regenerative medicine can add a powerful new dimension to this ecosystem. It can foster interdisciplinary collaboration between clinicians, researchers, biotech firms, device companies, and digital health platforms—strengthening overall innovation.
From a medical tourism perspective, India can offer advanced, accessible, and cost-effective care supported by high-quality expertise. While India is already a strong hub, regenerative medicine can further enhance its appeal.
However, the opportunity will not come from hype—it will come from building clinically credible, well-governed, and internationally presentable centres.
Looking ahead, what are Nuvana’s growth priorities?
Our approach to growth is centred on building depth before scale. Strengthening clinical systems and ensuring consistent outcomes is the foundation for any expansion.
Technology integration is another key focus—whether in patient assessment, protocol design, progress tracking, or long-term engagement. Technology should enhance precision, transparency, and continuity of care.
We also see strong value in partnerships—with medical experts, hospitals, wellness ecosystems, fitness platforms, and research-led collaborations that share a long-term vision. Finally, accessibility is critical. We want regenerative therapies to become more structured, understandable, and accessible across India—not limited to premium urban pockets.
Our goal is not just to grow Nuvana as a brand, but to contribute meaningfully to the evolution of this category in a credible, patient-centric, and future-ready way.
